Organization | The Wayne D. Kuni and Joan E. Kuni Foundation

The Wayne D. Kuni and Joan E. Kuni Foundation Report issue

Foundation Phase 1 Phase 2

Founded: Vancouver WA United States (2005)

Organization Overview

First Clinical Trial

2008

NCT00789776

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2010

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (9)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

allogeneic natural killer cells (1 trial)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (1 trial)

fludarabine (fludara) (1 trial)

mycophenolate (CellCept) (1 trial)

phenelzine (nardil) (1 trial)

sulforaphane (1 trial)

tacrolimus (prograf) (1 trial)

Drugs in Phase 1 Trials (1)

dribbles (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 10